Earnings Call Summary | Medtronic(MDT.US) Q4 2024 Earnings Conference
Earnings Call Summary | Medtronic(MDT.US) Q4 2024 Earnings Conference
The following is a summary of the Medtronic Plc (MDT) Q4 2024 Earnings Call Transcript:
以下是美敦力集團(MDT)2024年第四季度業績電話會議記錄摘要:
Financial Performance:
財務業績:
Medtronic experienced mid-single-digit revenue growth of over 5% for the full fiscal year 2024.
The company's earnings per share were $1.46, exceeding consensus.
Free cash flow increased by 14% over the previous year to $5.2 billion, indicating financial stability.
Medtronic returned $5.5 billion to shareholders through dividends and share repurchases.
For FY'25, the company projected organic revenue growth at 4% to 5%.
Long-term earnings guidance, excluding currency impact, predicts 9% to 11% growth.
美敦力在2024財年實現了超過5%的中等個位數收入增長。
該公司的每股收益爲1.46美元,超出市場預期。
自由現金流比上年增長14%,達到52億美元,表明財務穩定。
美敦力通過分紅和股票回購向股東返還了55億美元。
該公司預計25財年的有機收入增長爲4%至5%。
不包括貨幣影響在內的長期收益指引預計增長9%至11%。
Business Progress:
業務進展:
Medtronic is focusing on restoring their earnings power and is executing cost-out initiatives, pricing maintenance strategies, and maximizing operating overhead efficiencies.
Differentiated technology launches in markets like AFib, Structural Heart, robots, and diabetes position the company for durable growth.
Substantial growth was observed in the Diabetes business with the rollout of the MiniMed 780G system.
The company expanded its Robotics Surgical Technologies sector with the Hugo system.
Medtronic expresses confidence in fiscal '25 performance with continued innovation and growth.
In terms of business matters, Medtronic is improving pricing and transforming its product mix, including exiting lower-growth business lines.
Medtronic shows increased focus on emerging markets, particularly China, and has given emerging market leaders more control over resources for localized healthcare needs.
Medtronic's Spine franchise showed improvements and other businesses such as Surgical, AFib, and Hugo are their focus to drive them into growth drivers.
美敦力正專注於恢復盈利能力,正在執行成本削減計劃、爲維護策略定價,並最大限度地提高運營開銷效率。
在AFib、Structural Heart、機器人和糖尿病等市場推出的差異化技術使公司實現了持久增長。
隨着MiniMed 780G系統的推出,糖尿病業務實現了大幅增長。
該公司通過Hugo系統擴大了其機器人外科技術領域。
美敦力對25財年的持續創新和增長表現充滿信心。
在業務方面,美敦力正在改善定價並改變其產品組合,包括退出增長較低的業務線。
美敦力越來越關注新興市場,尤其是中國,並賦予了新興市場領導者對滿足本地醫療需求資源的更多控制權。
美敦力的Spine特許經營權有所改善,Surgical、AFib和Hugo等其他業務是他們的重點,以推動他們進入增長動力。
More details: Medtronic IR
更多詳情: 美敦力 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:欲了解更多詳情,請訪問投資者關係網站。本文僅供投資者參考,不構成任何投資建議。
譯文內容由第三人軟體翻譯。